Featured Research

from universities, journals, and other organizations

Using antibodies against immune deficiency

Date:
September 26, 2012
Source:
Charité - Universitätsmedizin Berlin
Summary:
Early, intensive therapy with a biotechnologically produced medication can provide significantly faster pain relief for patients with rheumatic joint inflammation. Damage to joints can also be reduced when the medication is applied right at the beginning of the illness, according to new research.

Early, intensive therapy with a biotechnologically produced medication can provide significantly faster pain relief for patients with rheumatic joint inflammation. Damage to joints can also be reduced when the medication is applied right at the beginning of the illness. A nationwide study sponsored by the Federal Ministry of Education and Research and conducted by Prof. Gerd-Rüdiger Burmester, director of the Medical Department, Division of Rheumatology and Clinical Immunology at Charité -- Universitätsmedizin Berlin, came to this conclusion.

Findings are published in the Annals of the Rheumatic Diseases.

In the study, the standard preparation of methotrexate was tested in comparison with a combined therapy of methotrexate and the biological agent (or biologic) adalimumab in treating rheumatoid arthritis. Biologics are a particular group of medication produced from living cells using methods of molecular biology. The medication exclusively targets particular messenger substances in the immune system. It clings to the body's inflammatory substances and renders them harmless. Pain, swelling and the progress of inflammation are thus prevented.

The medication tested by Prof. Burmester's work group is called adalimumab and was approved ten years ago. It is one of the most frequently prescribed biologics worldwide. It is prescribed when standard therapies are inadequate or when side effects develop. The Charité study examined how the medication affects patients with rheumatoid joint inflammation when the therapy is started immediately following diagnosis and not only when other therapies do not take effect.

Study participants had rheumatoid arthritis in the early stages, however, were considerably limited in their daily activities as a result of the symptoms. Half of the patients were given the combination therapy for six months and the other half serving as the comparison group was given the standard medication and a placebo. All test participants were then given methotrexate for another six months. Though both groups had comparable symptoms at the end of study, the group that was given the biologic experienced significantly faster pain relief. Furthermore, x-rays showed less bone damage in those patients compared to the placebo group. Prof. Burmester is confident: "We were able to show that early, intensive therapy with this biologic helps patients maintain their quality of life and prevent bone damage."


Story Source:

The above story is based on materials provided by Charité - Universitätsmedizin Berlin. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. Detert, H. Bastian, J. Listing, A. Weiss, S. Wassenberg, A. Liebhaber, K. Rockwitz, R. Alten, K. Kruger, R. Rau, C. Simon, E. Gremmelsbacher, T. Braun, B. Marsmann, V. Hohne-Zimmer, K. Egerer, F. Buttgereit, G.-R. Burmester. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Annals of the Rheumatic Diseases, 2012; DOI: 10.1136/annrheumdis-2012-201612

Cite This Page:

Charité - Universitätsmedizin Berlin. "Using antibodies against immune deficiency." ScienceDaily. ScienceDaily, 26 September 2012. <www.sciencedaily.com/releases/2012/09/120926092913.htm>.
Charité - Universitätsmedizin Berlin. (2012, September 26). Using antibodies against immune deficiency. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2012/09/120926092913.htm
Charité - Universitätsmedizin Berlin. "Using antibodies against immune deficiency." ScienceDaily. www.sciencedaily.com/releases/2012/09/120926092913.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins